Avagacestat
- Generic Name
- Avagacestat
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17ClF4N4O4S
- CAS Number
- 1146699-66-2
- Unique Ingredient Identifier
- TQ44WWY45Q
- Background
Avagacestat has been investigated for the basic science and treatment of Alzheimer Disease.
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 209
- Registration Number
- NCT00810147
- Locations
- 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸Global Medical Institutes, Llc, Princeton, New Jersey, United States
🇺🇸University Of Rochester, Rochester, New York, United States
Drug Interaction Study With a Potential Alzheimer's Disease Compound
Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)Drug: BMS-708163 + Cooperstown Cocktail
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2008-11-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00726726
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath